Astellas Pharma Statistics
Total Valuation
Astellas Pharma has a market cap or net worth of 27.85 billion. The enterprise value is 30.86 billion.
| Market Cap | 27.85B |
| Enterprise Value | 30.86B |
Important Dates
The last earnings date was Wednesday, February 4, 2026.
| Earnings Date | Feb 4, 2026 |
| Ex-Dividend Date | Mar 30, 2026 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.64% |
| Shares Change (QoQ) | -0.02% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 54.35% |
| Float | 1.79B |
Valuation Ratios
The trailing PE ratio is 13.52.
| PE Ratio | 13.52 |
| Forward PE | n/a |
| PS Ratio | 2.12 |
| PB Ratio | 2.47 |
| P/TBV Ratio | 15.88 |
| P/FCF Ratio | 10.73 |
| P/OCF Ratio | 9.54 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.98, with an EV/FCF ratio of 11.89.
| EV / Earnings | 14.98 |
| EV / Sales | 2.35 |
| EV / EBITDA | 7.98 |
| EV / EBIT | 11.67 |
| EV / FCF | 11.89 |
Financial Position
The company has a current ratio of 1.09, with a Debt / Equity ratio of 0.41.
| Current Ratio | 1.09 |
| Quick Ratio | 0.79 |
| Debt / Equity | 0.41 |
| Debt / EBITDA | 1.19 |
| Debt / FCF | 1.78 |
| Interest Coverage | 37.13 |
Financial Efficiency
Return on equity (ROE) is 19.82% and return on invested capital (ROIC) is 16.07%.
| Return on Equity (ROE) | 19.82% |
| Return on Assets (ROA) | 7.38% |
| Return on Invested Capital (ROIC) | 16.07% |
| Return on Capital Employed (ROCE) | 18.28% |
| Weighted Average Cost of Capital (WACC) | 4.03% |
| Revenue Per Employee | 963,327 |
| Profits Per Employee | 150,959 |
| Employee Count | 13,643 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 1.27 |
Taxes
In the past 12 months, Astellas Pharma has paid 422.63 million in taxes.
| Income Tax | 422.63M |
| Effective Tax Rate | 17.03% |
Stock Price Statistics
The stock price has increased by +69.25% in the last 52 weeks. The beta is 0.04, so Astellas Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.04 |
| 52-Week Price Change | +69.25% |
| 50-Day Moving Average | 13.68 |
| 200-Day Moving Average | 11.29 |
| Relative Strength Index (RSI) | 77.24 |
| Average Volume (20 Days) | 134,848 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Astellas Pharma had revenue of 13.14 billion and earned 2.06 billion in profits. Earnings per share was 1.14.
| Revenue | 13.14B |
| Gross Profit | 10.64B |
| Operating Income | 2.66B |
| Pretax Income | 2.48B |
| Net Income | 2.06B |
| EBITDA | 3.88B |
| EBIT | 2.66B |
| Earnings Per Share (EPS) | 1.14 |
Balance Sheet
The company has 1.62 billion in cash and 4.63 billion in debt, with a net cash position of -3.00 billion.
| Cash & Cash Equivalents | 1.62B |
| Total Debt | 4.63B |
| Net Cash | -3.00B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 11.26B |
| Book Value Per Share | 6.28 |
| Working Capital | 744.22M |
Cash Flow
In the last 12 months, operating cash flow was 2.92 billion and capital expenditures -324.13 million, giving a free cash flow of 2.60 billion.
| Operating Cash Flow | 2.92B |
| Capital Expenditures | -324.13M |
| Free Cash Flow | 2.60B |
| FCF Per Share | n/a |
Margins
Gross margin is 81.00%, with operating and profit margins of 20.22% and 15.67%.
| Gross Margin | 81.00% |
| Operating Margin | 20.22% |
| Pretax Margin | 18.88% |
| Profit Margin | 15.67% |
| EBITDA Margin | 29.53% |
| EBIT Margin | 20.22% |
| FCF Margin | 19.75% |
Dividends & Yields
This stock pays an annual dividend of 0.51, which amounts to a dividend yield of 3.25%.
| Dividend Per Share | 0.51 |
| Dividend Yield | 3.25% |
| Dividend Growth (YoY) | 1.07% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 44.71% |
| Buyback Yield | -0.64% |
| Shareholder Yield | 2.69% |
| Earnings Yield | 7.40% |
| FCF Yield | 9.32% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 2, 2014. It was a forward split with a ratio of 1.25.
| Last Split Date | Apr 2, 2014 |
| Split Type | Forward |
| Split Ratio | 1.25 |
Scores
Astellas Pharma has an Altman Z-Score of 2.24 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.24 |
| Piotroski F-Score | 7 |